$LIFE

Wang Lingke sold $4.6M of LIFE

Wang Lingke (President) sold 118,333 shares of Ethos Technologies Inc. (LIFE) at an average of $38.96 ($38.36–$39.67, $4.61M total) across 3 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wang Lingke
Published Sep 18, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LIFE
Bearish
medium confidence
Mentioned
$LIFE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIFEBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as a negative sentiment cue, though the pre‑arranged nature tempers the signal.

02

Market read

Primary relevance is to LIFE shareholders; broader market impact is limited.

03

What to watch

Potential upcoming corporate actions or financing needs that prompted the pre‑arranged sale.

Relevance 5/10Novelty 6/10Timing: after market close on 2026-09-18

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates the sale was pre‑scheduled.

Company-level read

Ticker impact

$LIFEBearishMedium confidence
Context

President Wang Lingke sold 118,333 shares for $4.6M via a 10b5-1 plan, reducing his stake to 1.54M shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $4.6M sale by a senior officer is material for a small‑cap, but the transaction is pre‑arranged, limiting immediate impact.

Market effects

Minimal; the sale does not affect the broader technology sector.

None; the filing is company‑specific.

Low; limited to investors tracking Ethos Technologies.

Counterpoint

The sale could be purely liquidity‑driven under a 10b5-1 plan, not a bearish signal.

Key entities

  • Ethos Technologies Inc.

    Issuer of the shares sold.

  • Wang Lingke

    President and insider selling shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LIFEMed

JPMorgan downgrades Ethos Technologies stock rating to neutral

JPMorgan downgraded Ethos Technologies (LIFE) to Neutral from Overweight, setting a $37 price target. The stock has surged 99% year-to-date. JPMorgan notes growth potential but cites balanced risk-reward and relative valuation concerns. Ethos reported Q2 2026 revenue of $189.6M, up 113% YoY, and raised full-year guidance to $727M-$731M. Other firms adjusted targets post-results.

$LIFEMed

Ethos (LIFE) Grows Revenue 113% While Margins Quietly Compress

Ethos Technologies (LIFE) reported Q2 revenue growth of 113% to $189.6M, with new policies up 133%. Gross profit margin was 98%, but net income rose only 5% to $19.5M. The company authorized a $100M stock buyback. Q3 revenue guidance is $160M-$164M, and full-year guidance is $727M-$731M. Margins compressed, with GAAP net loss of $146.9M for H1 2026 due to stock-based compensation.

$LIFEMedAI 9/10

Ethos (LIFE) Q2 2026 Earnings Call Transcript

Ethos Technologies (LIFE) reported Q2 2026 revenue of $189.6 million, up 113% Y/Y, with direct revenue $116.5 million (+131%) and third-party revenue $73.1 million (+90%). Adjusted EBITDA was $35.2 million (19% margin). Net income was $19.5 million. Full-year 2026 guidance: revenue $727-$731 million and adjusted EBITDA $119-$123 million. Up to $100 million Class A repurchase authorized.

$LIFEMed

Top SMid Cap Pick: Ethos Technologies Leads Citi’s Rankings

Citi analyst Ronald Josey named Ethos Technologies (LIFE) his top SMID-cap pick after the company’s Q2 results. Activated policies growth accelerated to 133% YoY, with 107,800 net activated policies. Revenue rose to $189.6M (+113% YoY). Ethos raised 2026 revenue guidance to $727M-$731M and adjusted EBITDA to $119M-$123M. Citi lifted its price target to $33 and kept Buy/High Risk.